002082 Wanbangde Pharmaceutical Holding Group
- 7.08
- +0.42+6.31%
About Wanbangde Pharmaceutical Holding Group Company
The company's main business is pharmaceutical manufacturing and the health industry, which mainly focuses on medical devices. It is a listed pharmaceutical manufacturing company in Shenzhen. The company is mainly engaged in R&D, production and sales of modern traditional Chinese medicines, chemical raw materials and chemical preparations, high-end medical device development, medical equipment services and hospital engineering services. The company's main products: huperzine, controlled release tablets, chlorpromazine hydrochloride tablets, cimetidine tablets, cefaclor granules, norfloxacin tablets, sulpiride tablets, lidocaine hydrochloride injections, bromhexine hydrochloride solution for inhalation, WP107, WP103, WP203A, lipoic acid, alanyl glutamine, SM13, medical equipment and hospital engineering integration services, disposable sterile medical polymer devices, orthopedic instruments. Company honors include China's top 20 construction profile enterprises, Zhejiang Province's top 100 fastest growing enterprises, Zhejiang Province's leading demonstration enterprise for transformation and upgrading, Zhejiang Province's clean production stage achievement enterprises, China's top 500 private enterprise manufacturing enterprises, “2022 China's Top 100 Chinese Medicine Enterprises”, “2023-2023 Outstanding Chinese Medicine Brand Enterprise”, and the company's bromhexine hydrochloride tablets are included in the “2023 Comprehensive Statistical Ranking of Chinese OTC Pharmaceutical Products - 2nd Place in Chemical Drugs and Cough-Relieving Phlegm Products”, Huixerine A and Formulation Development and Industrialized applications have obtained honors such as the “Science and Technology Achievement Registration Certificate”.
Company Profile
Company Executives
- Name
- Position
- Salary
- shouming zhao
- Chairman, Directors, General Manager, Convener of the Strategy and Investment Decision Committee, Acting Chief Financial Officer
- --
- hui zhuang
- Vice Chairman, Directors, Audit Committee Members
- --
- tongke liu
- Directors, Board Secretary, Deputy General Manager, Nomination Committee Members
- 600.00K
- hong lin
- Directors
- 187.50K
- bin han
- Directors, Member of the Remuneration and Assessment Committee
- --
- yuejiang zhou
- Independent Directors, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Audit Committee Convener
- 100.00K
- yanzhou zhang
- Independent Directors, Audit Committee Members, Remuneration and Assessment Committee Convener, Member of the Strategy and Investment Decision Committee
- 41.70K
- yang li
- Independent Directors, Nomination Committee Convener, Member of the Strategy and Investment Decision Committee
- 41.70K
- lisha chen
- Securities Affairs Representative
- --
- hugen wang
- Chairman of the Supervisory Board, Shareholder Supervisors
- 50.00K
- minghua jiang
- Audit Manager
- --
- gengsheng hu
- Employee Supervisors
- 187.50K
- xuannan jiang
- Employee Supervisors
- 41.70K
No Data